Kyntra Bio 10-Q: $44.1M Cash Into 2028, FG-3246 Killed, NovaQuest Cap Cut to $15M
KYNB is trading near its 52-week low of $3.02 (0.7% below the low) on elevated volume (2.3× avg).
Summary
Kyntra Bio's Q3 10-Q shows $1.8M revenue, $44.1M of cash and investments it says funds operations into 2028, the FG-3246 program terminated for insufficient efficacy, and a restructured NovaQuest royalty deal that cuts the remaining payment cap to $15.0M.
Key Events · Earnings and Guidance · KYNB
-
FG-3246 Program Terminated
A pre-specified Phase 2 interim analysis in mCRPC showed efficacy below the required threshold, so Kyntra closed enrollment and scrapped FG-3246 and FG-3180; it expects to save over $20 million in operating expenses in 2027 and 2028.
-
Q3 Results and Cash Runway
Revenue was $1.8 million versus $1.1 million a year ago and income from continuing operations was $0.2 million ($0.04 per share); cash, equivalents, investments and receivables totaled $44.1 million at September 30, 2026, which the company says funds operations into 2028.
-
NovaQuest Royalty Deal Restructured
The amended RIFA cut maximum aggregate payments from $125.0 million to $65.0 million in exchange for a $42.6 million upfront payment, leaving a $15.0 million remaining cap and producing a $14.0 million net gain on debt restructuring; Japan royalties and related collateral were released.
-
Phase 3 Contingent on Financing
The pivotal Phase 3 roxadustat trial in lower-risk MDS with high transfusion burden is planned for 1Q 2027, but only subject to a strategic partnership or an external capital raise.
Analysis · KYNB · Life Sciences
The quarter itself is small — $1.8M of revenue and $0.2M of income from continuing operations — but the filing tells the real story: Kyntra is now a one-asset company. FG-3246 was scrapped for insufficient efficacy, a move the company says saves over $20 million in 2027 and 2028, and the roxadustat Phase 3 in lower-risk MDS will only start in 1Q 2027 if a partner or new capital shows up. Cash, investments and receivables of $44.1M are stated to fund operations into 2028, though that runway assumes the cost cuts land. The NovaQuest royalty deal was restructured — maximum payments cut from $125.0M to $65.0M for a $42.6M upfront payment, leaving a $15.0M cap — which produced a $14.0M non-cash gain and frees the Japan royalties. Against that, the stock is still under a Nasdaq delisting determination; a hearing was held November 5, 2026 and the Panel's decision is pending.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KYNB was trading at $3.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13M. The 52-week trading range was $3.02 to $10.47. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.